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Abstract
Background: Identifying high-risk patients for platinum resistance is critical for improving clinical management of
ovarian cancer. We aimed to use automated image analysis of hematoxylin & eosin (H&E) stained sections to
identify the association between microenvironmental composition and platinum-resistant recurrent ovarian cancer.
Methods: Ninety-one patients with ovarian cancer containing the data of automated image analysis for H&E
histological sections were initially reviewed.
Results: Seventy-one patients with recurrent disease were finally identified. Among 30 patients with high stromal
cell ratio, 60% of the patients had platinum-resistant recurrence, which was significantly higher than the rate in
patients with low stromal cell ratio (9.80%, P < 0.001). Multivariate logistic regression analysis revealed elevated
CA125 level after 3 cycles of chemotherapy (P < 0.001) and high stromal cell ratio (P = 0.002) were the negative
predictors of platinum-resistant relapse. The area under the curve (AUC) of receiver operating characteristic (ROC)
curves of the models for predicting platinum-resistant recurrence with stromal cell ratio, normalization of CA125
level, and the combination of two parameters were 0.78, 0.79, and 0.89 respectively.
Conclusions: Our results demonstrated stromal cell ratio based on automated image analysis may be a potential
predictor for ovarian cancer patients at high risk of platinum-resistant recurrence, and it could improve the
predictive value of model when combined with normalization of CA125 level after 3 cycles of chemotherapy.
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Background
Ovarian cancer is the leading cause of death in patients
with gynecologic malignancies. In 2012, there were ap-
proximately 238,700 new cases of ovarian cancer and
151,900 deaths in the world [1]. Most women present with
advanced disease at diagnosis. Despite initial treatment
with primary debulking surgery followed by first-line tax-
ane and platinum-based chemotherapy, about 75% of pa-
tients will eventually relapse [2]. Disease that relapses ≥6
months after completion of platinum-based chemotherapy
is categorized as platinum-sensitive recurrence [3], while
disease that relapses < 6months after platinum-based
chemotherapy are defined as platinum-resistant recur-
rence [4]. Some patients initially present with platinum-
sensitive recurrent diseases, however, nearly all patients
with platinum-sensitive disease ultimately develop plat-
inum resistance, which results in death [5]. Therefore,
platinum resistance is a major determinant of poor out-
come in ovarian cancer. Predicting the risk of platinum re-
sistance will provide basis of improved therapeutic efficacy
in ovarian cancer.
In the past 20 years, the investigations of chemother-
apy resistance were mostly restricted to cancer cell in-
trinsic events, and the contributory effects of different
types of cells coexisting within the tumor were ignored
[6]. However, a large body of evidence has shown the
crosstalk between cancer cells as well as stromal cells in
tumor microenvironment enable tumor growth and
progression [7–11]. Moreover, microenvironment niches
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can promote chemoresistance within a tumor [12–15].
The abundance and characteristic of stromal cells and
immune cells in tumor microenvironment have been
demonstrated to lead to chemotherapy resistance in
multiple cancers [7, 15–19].
Recently, computer vision techniques have been
applied to tumor pathologic specimen and enable auto-
mated identification and classification of various cell
types in tumor microenvironment [20–23]. These
methods make rapid cell mapping in tumor pathologic
specimen and quantifying cellular composition across
tumor microenvironment. In one of our previous stud-
ies, we developed an automated image analysis system
for identifying and quantifying heterogeneous cell types
in ovarian cancer histological sections [24]. One of the
findings was that high amount of stromal cells in ovarian
cancer was significantly associated with poor overall
survival.
Therefore, in this paper, we aimed to (i) use automated
image analysis of histological sections to identify the as-
sociation between microenvironmental composition and
platinum-resistant recurrence in ovarian cancer, (ii)
develop a novel model to predict the risk of platinum-re-
sistant recurrence.
Methods
Patient selection
Ninety-one patients with ovarian cancer containing data
of automated image analysis for hematoxylin & eosin
(H&E) stained histological sections which were used in
our previous study were initially reviewed [24]. All
patients were stage III-IV disease and received primary
debulking surgery in our institute.
In these 91 patients, 71 patients had recurrent disease
and 20 patients did not. Only the 71 patients with recur-
rence were enrolled in this study. Clinical data regarding
patient demographics, surgical records, pathologic char-
acteristics, platinum-free interval, serum CA125 level
(normal level defined as ≤35 U/ml), treatment regimen
and follow-up were extracted from the hospital records.
Patients with disease that relapses < 6 months after com-
pletion of a platinum-based chemotherapy were defined
as platinum-resistant relapse. Informed consent was ob-
tained from all patients. Ethical approval were obtained
by the institutional review board of Sun Yat-sen Univer-
sity Cancer Center. All methods were carried out in ac-
cordance with the approved guidelines of our institute.
Histology image analysis and microenvironmental
composition quantification
Automated image analysis of H&E-stained whole-tumor
sections was described in our previous study [24]. In
brief, H&E histological sections of ovarian tumors were
generated, digitalized and analyzed using the R package
CRImage. A feature vector of 97 morphological and tex-
tural measurements derived from hematoxylin positive
nuclei were all subjected to a support vector machine
(SVM) for classification to identify single cells including
cancer cell, stromal cell and lymphocyte. The image ana-
lysis system was trained using a small set of training data
(900 cells provided by an expert pathologist) using SVM.
Experiments were performed to validate the system.
Then, cancer cells, stromal cells and lymphocytes were
quantified in each tumor section. And the cell ratio for
each sample was obtained, which was used to build
predictive models in this investigation.
Pathological scores
Pathological scores including percentage of cancer cells
and stromal cells for each H&E histological section were
given by a pathologist. Lymphocytic infiltration was
assessed as low, median, or high infiltration.
Statistical methods
Difference in platinum-resistant recurrence between
different groups was evaluated using Chi-square test.
The receiver operating characteristic (ROC) curve was
used to evaluate the performance of predictive models
and was created by plotting the true positive rate (TPR)
against the false positive rate (FPR) at various threshold
settings. The area under the curve (AUC) provided a
value description for the performance of the ROC curve.
The AUC score would be between 0 and 1. The higher
the value of AUC, the better the model was [25].
AUC ¼ Σ
n0
i ¼ 1 ri − ið Þ
n0  n1
¼
Σn0i ¼ 1 ri −
n0  n0 þ 1ð Þ
2
n0  n1 :
where ri was the rank of the ith positive participant in
the ranked list, and n0 and n1 were the numbers of the
positive and negative participants.
The predictive value of models including a single
parameter for platinum-resistant recurrence was deter-
mined using ROC curves. For combined parameters, the
predictive models were constructed according to the
following procedures. First we fitted multivariate logistic
regression model using the characteristics which univari-
ate logistic regression analysis suggested as significant
and the status of platinum-resistant recurrence as the
dependent variable. Then we calculated the probability P
values of each participant using these logistic regression
models. Third, we used the calculated P value as a
predictor to build the ROC curves. The AUC between
different models was compared using Z test by SAS 9.3
software. And the other data analysis were performed by
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SPSS Statistics 16.0 software (SPSS Inc., Chicago, IL,
USA). All the test were two sided and a p value < 0.05
was considered as significant. The key raw data have
been recorded at Sun Yat-sen University Cancer Center
for future reference (number RDDA2017000306).
Results
Clinicopathologic characteristics for patients with
recurrent ovarian cancer
The patient characteristics are presented in Table 1. In
the 71 patients with recurrent ovarian cancer, 49 were
platinum-sensitive relapse, and 22 were classified as
platinum-resistant recurrence. Patients with elevated
CA125 level after 3 cycles of chemotherapy during the
front-line treatment were significantly more likely to be
platinum-resistant recurrence when compared to those
with normalized CA125 level after 3 cycles of chemo-
therapy (68.4% vs 17.3%, P < 0.001). There was no sig-
nificant difference in age, residual disease status, FIGO
stage, and histologic types between the patients with
platinum-sensitive and platinum-resistant recurrence.
The association between microenvironmental
composition with automated image analysis and
platinum-resistant recurrence
Microenvironmental composition was provided by auto-
mated image analysis of ovarian cancer H&E histological
sections, which included the amounts of cancer cells,
stromal cells and lymphocytes. Then, we tested the asso-
ciation between microenvironmental composition and
platinum-resistant recurrence. The ROC curves were
used to determine the optimal cutoff points for cell ratio
to stratify patients with different recurrent type. In ROC
curve analysis for the stromal cell ratio, an optimal cut-off
point of 0.264 was selected (AUC= 0.78, P < 0.001). In
high stromal cell ratio group (stromal cell ratio > 0.264),
60% (18/30) of patients were platinum-resistant recur-
rence, compared with only 9.80% (4/41) of patients having
platinum-resistant recurrence in low stromal cell ratio
group (Chi-square test P < 0.001) (Fig. 1a). With respect to
tumor cell ratio, a best threshold of 0.683 was selected
(AUC= 0.77, P < 0.001). The frequency of platinum-resist-
ant recurrence in high tumor ratio group (tumor cell ra-
tio > 0.683) was only 10.5% (4/38), which was significantly
lower than the rate of platinum-resistant recurrence in
low tumor ratio group (54.5%, Chi-square test P <
0.001) (Fig. 1b). However, ROC curve analysis could
not find an optimal cut-off point regarding to lympho-
cyte ratio (AUC = 0.55, P = 0.526). Thus, we divided pa-
tients into three equal-size groups based on lymphocyte
ratio according to our previous study [24]. Neverthe-
less, there was no significant difference in the relapse
type between the low, median and high lymphocyte ra-
tio groups (P = 0.379) (Fig. 1c).
The association between microenvironmental
composition assessed by pathologist’s scores and
platinum-resistant recurrence
Microenvironmental composition was assessed by pa-
thologist’s scores of H&E histological sections. The ROC
curve analyses could not identify optimal thresholds for
cell ratio assessed by pathologist’s scores, including
cancer cell ratio (AUC = 0.53, P = 0.805), stromal cell ra-
tio (AUC = 0.46, P = 0.647) and lymphocyte infiltration
(AUC = 0.53, P = 0.682) to discriminate patients with
different recurrent types. Therefore, we defined 25% of
patients with the highest stromal cell ratio and cancer
cell ratio based on pathologist’s scores as high stromal
cell group and high cancer cell group, respectively. On
the other hand, we divided patients into three equal-size
groups based on lymphocyte infiltration. We found that
stromal cell ratio and cancer cell ratio based on patholo-
gist’s scores were not associated with the recurrent type in
ovarian cancer (Fig. 1d and e). Similarly, no significant dif-
ference in recurrent types was observed between the high,
median and low lymphocyte infiltration (Fig. 1f).
Multivariate logistic regression analysis for platinum-
resistant recurrent ovarian cancer
Then we determined the risk factors for platinum-resist-
ant recurrent disease by logistic regression. Since a
Table 1 Clinicopathologic characteristics for patients with
recurrent ovarian cancer
Characteristics Platinum-sensitive
recurrence (n = 49)
N (%)
Platinum-resistant
recurrence (n = 22)
N (%)
P value
Age 0.395
≤ 60 years 40 (71.4) 16 (28.6)
> 60 years 9 (60.0) 6 (40.0)
Residual disease 0.783
≤ 1 cm 25 (67.6) 12 (32.4)
> 1 cm 24 (70.6) 10 (29.4)
FIGO stage 0.115
Stage III 46 (71.9) 18 (28.1)
Stage IV 3 (42.9) 4 (57.1)
Histologic types 0.946
High-grade serous
carcinoma
44 (69.8) 19 (30.2)
Low-grade serous
carcinoma
2 (66.7) 1 (33.3)
Mucinous 1 (50.0) 1 (50.0)
Endometrioid 2 (66.7) 1 (33.3)
Normalization of CA125 level after 3 cycles of chemotherapy < 0.001
Yes 43 (82.7) 9 (17.3)
No 6 (31.6) 13 (68.4)
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significantly negative correlation between cancer and stro-
mal ratio was observed in our previous data [24], we only
included the stromal cell ratio and omitted the cancer
ratio in this logistic regression. The multivariate logistic
regression revealed that elevated CA125 level after 3 cycles
of chemotherapy (odds ratio: 18.06, P < 0.001) and high
stromal cell ratio (odds ratio: 14.69, P = 0.002) were the
significantly negative predictors of platinum-resistant
relapse of ovarian cancer (Table 2).
Predictive models for platinum-resistant recurrence of
ovarian cancer
When the stromal cell ratio based on automated image
analysis was included, the ROC curve for predicting
platinum-resistant recurrence yielded a sensitivity of
81.82%, specificity of 75.51%, positive predictive value of
60.00%, and negative predictive value of 90.24%. How-
ever, the model incorporating two parameters (stromal
cell ratio and normalization of CA125 level) for predict-
ing platinum-resistant recurrence achieved a sensitivity
of 95.50%, specificity of 65.30%, positive predictive value
of 55.26%, and negative predictive value of 96.97%
(Table 3, Fig. 2).
The two-parameter model had the lowest Akaike
information criterion (AIC) when compared with the
model with a single parameter of stromal cell ratio and
normalization of CA125 level (Table 3), which implied
the combined model was the best model. The AUC-ROC
of stromal cell ratio and normalization of CA125 level was
0.78 and 0.79, respectively. There was no significant differ-
ence in AUC between stromal cell ratio and normalization
of CA125 level (P = 0.84). The AUC-ROC of the
two-parameter model was 0.89. There was a marginally
significant difference in AUC between the model with
two parameters and with stromal cell ratio (Z = 1.61,
P = 0.107). On the other hand, a very small trend
Fig. 1 The association between microenvironmental composition (a-c stromal cell, tumor cell and lymphocyte ratio assessed by automated
image analysis, d-f stromal cell, tumor cell and lymphocyte ratio assessed by pathologist’s scores) and relapse types of ovarian cancer
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toward significant difference in AUC was observed
between the model with two parameters and with
normalization of CA125 level (Z = 1.28, P = 0.200).
Discussion
There is increasing evidence that heterogeneous compo-
nents in tumor microenvironment collectively promote
tumor chemoresistance [7, 11, 14]. However, most of studies
investigated the association between microenvironmental
Table 2 Logistic regression analyses on risk factors for platinum-resistant recurrent ovarian cancer
Variable Univariate Multivariate
Odds ratio (95%CI) P value Odds ratio (95%CI) P value
Age
≤ 60 years 1 1
> 60 years 1.67 (0.51–5.45) 0.398 2.05 (0.33–12.88) 0.446
Residual disease
≤ 1 cm 1 1
> 1 cm 0.87 (0.32–2.38) 0.783 0.38 (0.07–2.00) 0.251
FIGO stage
Stage III 1 1
Stage IV 3.41 (0.69–16.76) 0.131 7.52 (0.46–121.94) 0.156
Histologic types
High-grade serous carcinoma 1 1
Others 1.39 (0.30–6.41) 0.673 2.05 (0.24–17.49) 0.512
Normalization of CA125 level after 3 cycles of chemotherapy
Yes 1 1
No 16.00 (4.66–54.91) < 0.001 18.06 (3.69–88.38) < 0.001
Stromal cell ratio
Low 1 1
High 13.88 (3.92–49.11) < 0.001 14.69 (2.79–77.35) 0.002
Table 3 Predictive models for platinum-resistant recurrent
ovarian cancer
Model I Model II Model III
Sensitivity 81.82% 72.70% 95.50%
Specificity 75.51% 85.70% 65.30%
Positive predictive value 60.00% 69.57% 55.26%
Negative predictive value 90.24% 87.50% 96.97%
AIC 70.60 68.44 56.49
Youden index 0.57 0.58 0.61
AUC 0.78 0.79 0.89
95% CI for AUC 0.66–0.89 0.67–0.92 0.81–0.97
A. Stromal cell ratio based on automated image analysis
B. Normalization of CA125 level after 3 cycles of chemotherapy
Model I: A
Model II: B
Model III: A + B
AIC Akaike information criterion
AUC Area under curve
Fig. 2 ROC curves of predictive models for platinum resistant
relapse of ovarian cancer. (i) Stromal cell ratio based on automated
image analysis (ii) Normalization of CA125 level after 3 cycles
of chemotherapy
Lan et al. BMC Cancer          (2019) 19:159 Page 5 of 8
components and chemoresistance by microarrays [26],
sequencing technology [27], Polymerase Chain Reaction
(PCR) [28] and immunohistochemistry [29]. Computational
analysis of pathological images with quantitative and object-
ive nature provides a new opportunity for understanding the
tumor microenvironment. Several studies used automated
image analysis to quantify the microenvironmental compos-
ition [20–23]. We previously applied automated image ana-
lysis on ovarian cancer and showed the stromal cell ratio
was an independent prognostic factor [24]. A key advantage
of this method is that it is based on fully automated image
analysis of H&E-stained histology slides generated as part of
clinical routine, therefore does not rely on antibodies and
represents an opportunity to develop cost-effective bio-
markers. However, how the quantification of the microenvi-
ronmental composition can be useful beyond prognostic
biomarkers and for guiding ovarian cancer treatment
remained elusive. This inspired us to design our current
study, in which we proposed that a simple yet effective
measure of stromal cell ratio was a potential predictive bio-
marker for ovarian cancer platinum treatment resistance.
Here, we further demonstrated the association between mi-
croenvironmental composition and platinum-resistant re-
lapse of ovarian cancer using automated pathological image
analysis as compared to established clinical variables.
One of the important findings in this study was that
high stromal cell ratio as well as low cancer cell ratio
based on computational analysis of routinely generated
pathological sections were significantly correlated with
high frequency of platinum-resistant recurrence. The
majority of stromal cells identified by image analysis were
fibroblasts and myofibroblasts according to α-smooth
muscle actin (α-SMA) staining which has been reported in
our previous study [24]. Mhawech-Fauceglia et al. [29] re-
vealed that the level of fibroblast activation protein alpha
(FAP) expressed by fibroblasts in tumor stroma was asso-
ciated with platinum resistance and shorter recurrence in
ovarian cancer, which was consistent with our observa-
tion. Thus far, the mechanism underlying the acquisition
of platinum resistance in stromal cells has been rarely
elucidated. Carcinoma-associated fibroblasts (CAFs) are
abundant and heterogeneous stromal cells in tumor
microenvironment. Recently, Su et al. found that
CD10+GPR77+CAFs could promote tumor formation and
chemoresistance [15]. They demonstrated that mechanis-
tically, CD10+GPR77+CAFs were driven by persistent
NF-kB activation via p65 phosphorylation and acetylation,
which was maintained by complement signaling via
GPR77, a C5a receptor [15].
However, we could not stratify patients with distinctly
different relapse types by pathologist’s scores for stromal,
cancer cell ratio as well as lymphocyte infiltration. Such
difference could be explained by a number of factors.
Firstly, pathological scoring is highly important in
research and clinical settings. However, for tasks without
well-established guidelines, such as stromal cell scoring
which is often not part of clinical assessment, it could be
prone to variability. Secondly, because of the time-con-
suming nature of the task, which is to estimate the
amount of stromal cells in whole-tumor section slides,
the pathologist can only provide visual estimation based
on scoring of five high-power fields. In contrast, auto-
mated image analysis enumerates all cells in the entire
slides to provide quantitative counts, thereby relieving
pathologists from repetitive tasks such as cell counting.
The results suggested that automated image analysis by
quantifying the amount of cells can generate accurate
data and reveal tumor features correlating with treat-
ment outcome, highlighting an opportunity for perform-
ing repetitive tasks using computers and providing a
new method for studying platinum-resistant relapse of
ovarian cancer.
In this study, multivariate logistic regression revealed
the stromal cell ratio based on automated image analysis
and normalization of CA125 level after 3 cycles of
chemotherapy were the significant predictors of
platinum-resistant recurrent ovarian cancer. CA125 is a
widely used biomarker of ovarian cancer for evaluating
disease and monitoring the treatment efficacy [30, 31].
Feng et al. found that increased preoperative CA125
level was associated with a low prognostic nutritional
index (PNI), which could reflect both the nutritional and
immunological status of the host [32]. Furthermore,
Miao et al. reported that the PNI could help predict the
platinum resistance of ovarian cancer [33]. However,
limited researches investigated the direct association
between the CA125 level and the platinum resistance of
ovarian cancer. In the current study, the AUC-ROC of
model including normalization of CA125 level after 3
cycles of chemotherapy was 0.79, with a sensitivity of
72.70% and specificity of 85.70%. It was noteworthy that
the AUC-ROC was increased to 0.89 when the model
containing stromal cell ratio combined with
normalization of CA125 level. Although the increased
AUC of two-parameter model was only marginally sig-
nificant comparing with stromal cell ratio, and achieved
a very small trend toward significant difference compar-
ing with CA125 level, we considered that the number of
subjects was too small to reach significant difference.
Our findings implied that stromal cell ratio may be used
to improve the predictive model when combined with a
commonly used biomarker CA125. While this remains
to be validated, early detection of high-risk patients
could have significant implications for improved clinical
management of ovarian cancer.
There were a number of limitations of our study,
including that the lack of validation cohorts that have all
these data types for this relative rare cancer type, the
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need for antibody staining to more closely examine
diverse stromal cell populations and the need to under-
stand the mechanisms underlying platinum resistance.
Moreover, it should be noted that our data were re-
stricted in patients with recurrent ovarian cancer, which
might limit the generalizability of our results to broad
population.
Conclusion
In summary, automated image analysis quantifying mi-
croenvironmental components provides a new method
for studying platinum resistant relapse of ovarian cancer.
Stromal cell ratio based on image analysis may be a
potential predictor for ovarian cancer patients at high
risk of platinum resistant relapse. Stromal cell ratio
could improve the predictive value of the model when
combined with normalization of CA125 level after 3 cy-
cles of chemotherapy.
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